Target Discovery and Validation Reviews and Protocols

More documents

Recommendations

Info

Pancreatic Cancer 89 49. Rabilloud, T., Carpentier, G., and Tarroux, P. (1988) Improvement and simplification of low-background silver staining of proteins by using sodium dithionite. Electrophoresis 9, 288–291. 50. Ishihama, Y., Rappsilber, J., Andersen, J. S., and Mann, M. (2002) Microcolumns with self-assembled particle frits for proteomics. J. Chromatogr. A 979, 233–239. 51. Pruitt, K. D., Tatusova, T., and Maglott, D. R. (2005) NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res. 33, D501–D504.
Page 1 and 2:
METHODS IN MOLECULAR BIOLOGY 360 T
Page 3 and 4:
M E T H O D S I N M O L E C U L A R
Page 5 and 6:
© 2007 Humana Press Inc. 999 River
Page 7 and 8:
vi Preface get. Approaches to targe
Page 9 and 10:
viii Contents 10 Transgenic Animal
Page 11 and 12:
x Contributors SAHOHIME MATSUMOTO
Page 13 and 14:
xii Contents of Volume 2 12 Validat
Page 15 and 16:
2 Sioud disease pathogenesis and pe
Page 17 and 18:
4 Sioud A more fruitful approach fo
Page 19 and 20:
6 Sioud both transient and permanen
Page 21 and 22:
8 Sioud serum biomarkers. This syne
Page 23 and 24:
10 Sioud Fig. 2. Schematic of targe
Page 25 and 26:
12 Sioud 13. Magin, T. M. (1998) Le
Page 28 and 29:
Harnessing the Human Genome 15 The
Page 30 and 31:
Harnessing the Human Genome 17 Fig.
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Harnessing the Human Genome 23 The
Page 38 and 39:
Page 40 and 41:
Harnessing the Human Genome 27 repr
Page 42 and 43:
Harnessing the Human Genome 29 14.
Page 44:
Harnessing the Human Genome 31 45.
Page 47 and 48:
34 Imoto et al. (4,5), and Bayesian
Page 49 and 50:
36 Imoto et al. 2. Materials Two ty
Page 51 and 52: 38 Imoto et al. Fig. 3. Graphical v
Page 53 and 54: 40 Imoto et al. Fig. 5. Result of t
Page 55 and 56: 42 Imoto et al. p(D |G) = ∫ p(D,
Page 57 and 58: 44 Imoto et al. β k (k = 1,…,q j
Page 59 and 60: 46 Imoto et al. Fig. 7. Partial res
Page 61 and 62: 48 Imoto et al. Fig. 8. Strategy to
Page 63 and 64: 50 Imoto et al. Fig. 9. (continued)
Page 65 and 66: 52 Imoto et al. Table 3 List of Roo
Page 67 and 68: 54 Imoto et al. 5. De Hoon, M. J. L
Page 69 and 70: 56 Imoto et al. 39. Kamimura, T., S
Page 71 and 72: 58 Beaty et al. cytotoxic drugs and
Page 73 and 74: 60 Beaty et al. Fig. 1. Principles
Page 75 and 76: 62 Beaty et al. oligonucleotide mic
Page 77 and 78: 64 Beaty et al. 3. The 12% polyacry
Page 79 and 80: 66 Beaty et al. 2.3.3. Protein Stai
Page 81 and 82: 68 Beaty et al. 3.1.3. Labeling of
Page 83 and 84: 70 Beaty et al. 1 µL of the anneal
Page 85 and 86: 72 Beaty et al. 4. Phenol:cholorfor
Page 87 and 88: 74 Beaty et al. 19. Wash twice with
Page 89 and 90: 76 Beaty et al. The Following Volum
Page 91 and 92: 78 Beaty et al. using a protein ass
Page 93 and 94: 80 Beaty et al. 6. Shake the gel fo
Page 95 and 96: 82 Beaty et al. Fig. 2. Preparation
Page 97 and 98: 84 Beaty et al. search in. A widely
Page 99 and 100: 86 Beaty et al. 3. Kern, S. E., Hru
Page 101: 88 Beaty et al. 34. Peters, D. G.,
Page 105 and 106: 92 Sørlie
Page 107 and 108: 94 Sørlie are based on such a plat
Page 109 and 110: Fig. 2. Cluster analysis of a subse
Page 111 and 112: 98 Sørlie are not internally heter
Page 113 and 114: 100 Sørlie termed luminal subtype
Page 115 and 116: 102 Sørlie Fig. 4. Kaplan-Meier an
Page 117 and 118: 104 Sørlie this cluster of genes v
Page 119 and 120: 106 Sørlie Fig. 5. Cluster of gene
Page 121 and 122: 108 Sørlie Fig. 6. Concordance bet
Page 123 and 124: 110 Sørlie Acknowledgments All col
Page 125 and 126: 112 Sørlie 31. Slamon, D. J., Clar
Page 127 and 128: 114 Sørlie 62. Bergh, J., Norberg,
Page 129 and 130: 116 Røsok and Sioud 1.1. Selection
Page 131 and 132: 118 Røsok and Sioud Compared with
Page 133 and 134: 120 Røsok and Sioud 1.1.7. Differe
Page 135 and 136: 122 Røsok and Sioud a powerful app
Page 137 and 138: 124 Røsok and Sioud represent each
Page 139 and 140: 126 Røsok and Sioud splicing may b
Page 141 and 142: 128 Røsok and Sioud 22. Liang, P.
Page 144 and 145: 7 Genome-Wide Screening by Using Sm
Page 146 and 147: RNAi Libraries 133 Fig. 2. Schemati
Page 148 and 149: RNAi Libraries 135 pathways. Thus,
Page 150 and 151: RNAi Libraries 137 3.3.1. Puromysin
Page 152 and 153:
RNAi Libraries 139 Fig. 4. Example
Page 154 and 155:
RNAi Libraries 141 12. Paddison, P.
Page 156 and 157:
8 Hammerhead Ribozyme-Based Target
Page 158 and 159:
Hammerhead Ribozymes 145 Libraries
Page 160 and 161:
Hammerhead Ribozymes 147 3.1.1. Pre
Page 162 and 163:
149 Fig. 2. Discovery of genes invo
Page 164 and 165:
Hammerhead Ribozymes 151 3.3. Recov
Page 166:
Hammerhead Ribozymes 153 9. Onuki,
Page 169 and 170:
156 Erfle and Pepperkok 2. Material
Page 171 and 172:
158 Erfle and Pepperkok cells away
Page 173 and 174:
160 Erfle and Pepperkok 5. The stai
Page 176 and 177:
10 Transgenic Animal Models in Biom
Page 178 and 179:
Transgenic Models 165 giant mice ex
Page 180 and 181:
Transgenic Models 167 2.1.3. Use of
Page 182 and 183:
Transgenic Models 169 a recombinant
Page 184 and 185:
Transgenic Models 171 Fig. 3. Diffe
Page 186 and 187:
Transgenic Models 173 FRT sites are
Page 188 and 189:
Transgenic Models 175 Fig. 4. Diffe
Page 190 and 191:
Transgenic Models 177 models, the b
Page 192 and 193:
Transgenic Models 179 Fig. 6. Vecto
Page 194 and 195:
Transgenic Models 181 vectors can d
Page 196 and 197:
Transgenic Models 183 then used to
Page 198 and 199:
Transgenic Models 185 be fixed and
Page 200 and 201:
Transgenic Models 187 period of inc
Page 202 and 203:
Transgenic Models 189 (142). Genes
Page 204 and 205:
Transgenic Models 191 from differen
Page 206 and 207:
Transgenic Models 193 Acknowledgmen
Page 208 and 209:
Transgenic Models 195 34. Thermes,
Page 210 and 211:
Transgenic Models 197 68. Gupta, S.
Page 212 and 213:
Transgenic Models 199 105. Weber, W
Page 214 and 215:
Transgenic Models 201 138. Ranger,
Page 216 and 217:
11 Keratin Transgenic and Knockout
Page 218 and 219:
Keratin Transgenics and Knockouts 2
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
211 K17 K17 Hair follicles, Alopeci
Page 226 and 227:
213 K6a K6a Hair follicles; Lysis o
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264:
Page 267:
254 Skovseth, Küchler, and Haralds
Page 270 and 271:
In Vivo Assay of Human Angiogenesis
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
13 A Murine Model for Studying Hema
Page 284 and 285:
Heart Failure and Immunity 271 We h
Page 286 and 287:
Heart Failure and Immunity 273 3.1.
Page 288:
Heart Failure and Immunity 275 6. W
Page 291 and 292:
278 Sioud gene products have been d
Page 293 and 294:
280 Sioud Fig. 1. Schematic of hema
Page 295 and 296:
282
Page 297 and 298:
284
Page 299 and 300:
286 Sioud selection), whereas thymo
Page 301 and 302:
288 Sioud Fig. 5. Affinity maturati
Page 303 and 304:
290 Sioud Fig. 6. A second signal i
Page 305 and 306:
292 Sioud Fig. 7. Bridging between
Page 307 and 308:
294 Sioud Fig. 8. Schematic of clas
Page 309 and 310:
296 Sioud Fig. 10. Critical molecul
Page 311 and 312:
298 Sioud In contrast to the expres
Page 313 and 314:
300 Sioud tumor infiltrating lympho
Page 315 and 316:
302 Sioud (see Chapter 15, Volume 1
Page 317 and 318:
304 Sioud display if the foreign pr
Page 319 and 320:
306 Sioud Fig. 13. Immunoscreening
Page 321 and 322:
308 Sioud molecular techniques have
Page 323 and 324:
310 Sioud Although much of the init
Page 325 and 326:
312 Sioud Because of their importan
Page 327 and 328:
314 Sioud 22. He, X., Janeway, C. A
Page 329 and 330:
316 Sioud 59. Sahin, U., Tureci, O.
Page 331 and 332:
318 Sioud 91. Golgher, D., Jones, E
Page 333 and 334:
320 Jäger Furthermore, this immune
Page 335 and 336:
322 Jäger Antigens that are tumor-
Page 337 and 338:
324 Jäger 2. Nakano, O., Sato, M.,
Page 339 and 340:
326 Jäger 31. Chen, Y. T., Gure, A
Page 341 and 342:
328 Le Naour dependent on CD8+ cyto
Page 343 and 344:
330 Le Naour Fig. 1. To illustrate
Page 345 and 346:
332 Le Naour heterogeneity of HCC,
Page 347 and 348:
334 Le Naour 15. Le Naour, F., Mise
Page 349 and 350:
336 Cekaite, Hovig, and Sioud Yeast
Page 351 and 352:
338 Cekaite, Hovig, and Sioud diffe
Page 353 and 354:
340
Page 355 and 356:
342 Cekaite, Hovig, and Sioud nonra
Page 357 and 358:
344 Cekaite, Hovig, and Sioud 3. Ue
Page 359 and 360:
346 Cekaite, Hovig, and Sioud 32. T
Page 361 and 362:
348 Cekaite, Hovig, and Sioud 65. L
Page 363 and 364:
350 Index Centroblast, 289 Centrocy
Page 365 and 366:
352 Index L Labeling mRNA, 62 Large
Page 367:
354 Index Tetraploid embryos, 239 g
show all

Target Discovery and Validation Reviews and Protocols

Create successful ePaper yourself

Delete template?

Save as template?